The earnings call transcript discusses MM 120 for generalized anxiety disorder patients, highlighting broad access due to a wide label. Updates on GAD trials enrollment will follow industry standards, with a sample size reestimation analysis expected after 100 patients complete week 12 to maintain study power.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay